Company Overview

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

  • Name

    Pfizer Inc.

  • CEO

    Dr. Albert Bourla D.V.M., Ph.D.

  • Website

    www.pfizer.com

  • Sector

    Pharmaceuticals

  • Year Founded

    1849

Profile

  • Market Cap

    $168.07B

  • EV

    $231.11B

  • Shares Out

    5,666.7M

  • Revenue

    $55.17B

  • Employees

    88,000

Margins

  • Gross

    60.16%

  • EBITDA

    18.06%

  • Operating

    5.95%

  • Pre-Tax

    -7.55%

  • Net

    -4.7%

  • FCF

    8.72%

Returns (5Yr Avg)

  • ROA

    8.96%

  • ROTA

    38.23%

  • ROE

    21.17%

  • ROCE

    12.55%

  • ROIC

    10.63%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $33.23

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $7,100M

  • Net Debt

    $62.76B

  • Debt/Equity

    0.79

  • EBIT/Interest

    1.11

Growth (CAGR)

  • Rev 3Yr

    0.03%

  • Rev 5Yr

    0.56%

  • Rev 10Yr

    0.92%

  • Dil EPS 3Yr

    -40.78%

  • Dil EPS 5Yr

    -26.36%

  • Dil EPS 10Yr

    -11.51%

  • Rev Fwd 2Yr

    3.87%

  • EBITDA Fwd 2Yr

    24.72%

  • EPS Fwd 2Yr

    24.72%

  • EPS LT Growth Est

    9.59%

Dividends

  • Yield

  • Payout

    -361.96%

  • DPS

    $1.66

  • DPS Growth 3Yr

    2.53%

  • DPS Growth 5Yr

    3.47%

  • DPS Growth 10Yr

    5.2%

  • DPS Growth Fwd 2Yr

    2.11%

NYSE:PFE